Nutrition 21's research further boost Diachrome

By staff reporter

- Last updated on GMT

Related tags: Chromium picolinate, Nutrition, Diabetes

Nutrition 21 is publicizing the results of a study conducted on its
patented Diachrome as significantly improving the glycemic levels
of patients with poor blood sugar levels being treated with oral
anti-diabetic medication.

The New York State-based company's branded combination of chromium picolinate and biotin was used in a 447 subject, randomized, double-blind, placebo-controlled clinical study. "This study shows that adding Diachrome to anti-diabetic medications can help patients reach their blood sugar goal simply, effectively and safely,"​ said Nutrition 21's lead investigator in the study, Cesar Albarracin. Chromium is an essential trace mineral that occurs naturally in small amounts in some foods, including brewer's yeast, lean meat, cheese, pork kidney and whole grain bread and cereals. It is poorly absorbed by the human body but is known to play an important role in the metabolism of carbohydrate, fat and protein. Patients in the treatment group saw an additional absolute decrease of 1.76 percent in glycemic control (A1C) compared with the placebo group, who showed an absolute decrease of 0.54 percent. "Uncontrolled, obese and overweight type 2 diabetes patients present an ongoing clinical challenge to health professionals,"​ said Albarracin. "Prescribing another anti-diabetic medication can increase the risk of unwanted side effects, including weight gain or hypoglycemic events, and could place an added financial burden on the patient."​ Lowering A1C by as little as one percent can delay or prevent serious complications, according to Nutrition 21, thereby reducing diabetes-related deaths. According to the American Diabetes Association, overall seven percent of the population have diabetes - that is to say, 20.8 Americans. Recent research from Yale University, published in the journal Diabetes Technology and Therapeutics,​ showed a daily supplement of chromium picolinate and biotin improved glucose tolerance by 15 percent compared to placebo. The study looked at the effect of Diachrome on the glycaemic control and blood lipids of 36 overweight or obese people with type 2 diabetes. Lead author Gregory Singer wrote: "This pilot study demonstrates that supplementation with a combination of chromium picolinate and biotin in poorly controlled patients with diabetes receiving antidiabetic therapy improved glucose management and several lipid measurements.""Chromium picolinate /biotin supplementation may represent an effectuive adjunctive nutritional therapy to people with poorly controlled diabetes with the potential for improving lipid metabolism."​ Source: Diabetes Technology and Therapeutics​Volume 8, Number 6, Pages 636-643 "The effect of chromium picolinate and biotin supplementation on glycaemic control in poorly controlled patients with type-2 diabetes mellitus: a placebo-controlled, double-blinded, randomized trial"​ Authors: G.M. Singer, J. Geohas

Related topics: Research

Related news

Show more

Follow us


View more